Quality Level
material
(flouropolymer), (thermoplastic elastomer), C-Flex® tubing (374), device, polypropylene , silicone (thermoplastic elastomer), tubing (Pharma 65)
agency
according to ISO 11137, meets EN 2.6.14, meets JP 4.01, meets USP 85
sterility
sterile; γ-irradiated (level of 25-40 kGy)
product line
Mobius®
packaging
package of 5 ×
parameter
-196- 60 °C temp. range (-321- 140 °F), 0.3 bar max. pressure (4.4 psi), 150 mL process volume
technique(s)
buffer exchange: suitable, media fill: suitable
capacity
250 mL
impurities
<0.25 EU/mL Aqueous extraction (LAL test)
fitting
plug (plug-end 1/8"HB), port (end-ported 2x 1/8"HB)
application(s)
cell therapy
gene therapy
life science and biopharma
liquid processing
mAb
ophthalmics
parenterals
pharma/biopharma processes
viral therapy
waste management
storage temp.
10-30°C
General description
Our Mobius® High Cell Density Cryopreservation (HCDC) Assembly (-196C) is a single-use assembly specially designed to facilitate the freeze and thaw of cryopreserved cells in liquid nitrogen vapor phase (? -196°C). Available in two assembly bag sizes of 100 mL and 250 mL, our Mobius® HCDC Assembly (-196C) enables seed train inoculation with cells at a higher cell density and larger volume compared to the traditional seed train process using vials, which significantly accelerates the cell expansion process. Our Mobius® single-use assembly also provides a closed processing environment preventing contamination while improving process reproducibility.
Application
Biochem/physiol Actions
Application
Features and Benefits
Designed to facilitate the freeze and thaw of cryopreserved cells in liquid nitrogen vapor phase ( -196°C).
Packaging
Other Notes
Pinch clamp: Nylon
Legal Information
法规信息
此项目有
商品
High cell density cryopreservation (HCDC) is a closed processing alternative to the traditional seed train expansion process. Learn more about the benefits of HCDC.
相关内容
生物制药开发商需要高效、高产的上游工艺,以生产高质量的单克隆抗体(mAbs)及其他类型的重组蛋白。工艺强化能够使他们的生产策略更具前瞻性,降低成本,并提高生产设施的灵活性。
Biopharmaceutical developers need efficient, productive upstream processes that deliver high quality monoclonal antibodies (mAbs) and other types of recombinant proteins. Process intensification can future-proof their manufacturing strategies, reduce costs, and increase facility flexibility.